Back to top

Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight

Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Silence Therapeutics (SLN) with an Overweight rating and no price target Silence is...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Silence Therapeutics PLC Sponsored ADR (SLN)